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Objective. To determine whether a combination of borage seed oil rich in gamma linolenic acid (GLA) and fish oil rich in
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is superior to either oil alone for treatment of rheumatoid arthritis
(RA). Methods. Patients were randomized into a double-blind, 18-month trial. Mixed effects models compared trends over time
in disease activity measures. Results. No significant differences were observed in changes in disease activity among the three
randomized groups. Each group exhibited significant reductions in disease activity (DAS28) at 9 months (fish: −1.56[−2.16, −0.96],
borage: −1.33[−1.83, −0.84], combined: −1.18[−1.83, −0.54]) and in CDAI (fish: −16.95[−19.91, −13.98], borage: −11.20[−14.21, −8.19],
and combined: −10.31[−13.61, −7.01]). There were no significant differences in change of RA medications among the three groups.
Reduced disease activity in study patients was similar to matched patients from an RA registry, and reduction in DMARD use
was greater (𝑃 < 0.03) in study patients. Conclusion. All 3 treatment groups exhibited similar meaningful clinical responses after
9 months, improvements which persisted for 18 months, and a response similar to matched patients from an RA registry. Study
patients were able to reduce DMARD therapy given in combination with TNF antagonists to a greater extent than registry patients.
This paper is dedicated to the memory of Dr. John T. Sharp, M.D., a pioneer and
innovator in the field of musculoskeletal radiology.
1. Introduction
Abundant experimental evidence supports the view that
eicosanoids participate in development and regulation of
immunological and inflammatory responses [1–4]. Because
essential fatty acids are precursors to eicosanoids and are
important determinants of cell function, they influence
immune responses [5]. A disease such as rheumatoid arthri-
tis (RA), characterized by abnormal immune responses,
inflammation, and joint tissue injury [6], may therefore be
amenable to control by treatment with oils rich in particular
polyunsaturated fatty acids.
Gamma linolenic acid (GLA: 18 : 3 omega 6) is an essen-
tial fatty acid found in borage seed oil. GLA is metabolized
to dihomogamma linolenic acid (DGLA; 20 : 3 omega 6),
the immediate precursor of prostaglandin E
1
(PGE
1
), an
eicosanoid with anti-inflammatory and immunoregulatory
properties [7]. In addition, GLA cannot be converted to
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inflammatory leukotrienes by 5-lipoxygenase. Instead, it is
converted to 15-hydroxy DGLA, which has the virtue of
suppressing 5-lipoxygenase activity [8]. GLA and DGLA
also modulate immune responses in an eicosanoid indepen-
dent manner by acting directly on T lymphocytes [9], and
GLA suppresses acute and chronic inflammation, including
arthritis, in animal models [10]. More importantly, in several
randomized, placebo-controlled trials in RA patients, GLA in
borage or primrose seed oils reduced synovitis and the need
for nonsteroidal anti-inflammatory agents [11–13].
Fish oil, rich in eicosapentaenoic acid (EPA; 20 : 5 omega
3) and docosahexaenoic acid (DHA; 22 : 6 omega-3), sup-
presses formation of the inflammatory eicosanoids PGE
2
,
thromboxane A
2
(TXA
2
), and leukotriene B
4
(LTB
4
). The
LTB
5
which is produced is a far less potent mediator
than LTB
4
. Each of 12 randomized, placebo-controlled, and
double-blind trials of fish oil in RA documents clinical
improvement, including reductions in duration of morning
stiffness, number of tender joints, joint pain, time to fatigue,
and increased grip strength. Those studies that monitored
NSAID use suggest that fish oil treatment has an NSAID
sparing effect [14, 15].
A combination of EPA and GLA enriched oils exhibits
synergy in reduction of synovitis in animal models [16],
and treatment of RA patients with black currant seed oil,
which contains both the n-3 fatty acid alpha linolenic acid
(converts to EPA) and the n-6 GLA, suppresses synovitis in
these patients [17]. These results suggest that a combination
of GLA and EPA may be a more useful therapy for RA than
each fatty acid alone.Therefore, we carried out a phase 3 trial
of borage seed oil, fish oil, and a combination of the two oils in
patients with RA and active synovitis, to determine whether
the combination is superior to treatment with either oil alone.
2. Study Design
The study was an 18-month randomized, double-blind com-
parison of borage seed oil, fish oil, and the combination
of both oils in RA patients with synovitis. Patients were
evaluated at 3-month intervals. The protocol was reviewed
and approved by the Committee for the Protection of Human
Subjects in Research at the University of Massachusetts
Medical School and by the Food and Drug Administration.
Subsequent approvals were obtained from Review Boards at
the University of Alabama, Geisinger Clinic, Fallon Health
Care, and the New England IRB. Written informed consent
was obtained from each patient.
3. Eligibility
Patients were eligible to participate in the study if they hadRA
according to the 1987 criteria of the American Rheumatism
Association [18], were in functional class I, II, or III according
to the revised criteria of the American College of Rheuma-
tology [19], and were between the ages of 18 and 85. Patients
had active disease as manifest by at least 3 swollen joints
and 6 tender joints at the time of enrollment. In addition,
patients had an erythrocyte sedimentation rate (ESR) of
>28mm/hr or morning stiffness of at least 45min. Patients
were on a stable dose of disease modifying antirheumatic
drugs (DMARDs) and/or biologic agents for at least 2months
before the screening visit, with a total duration of therapy
of at least 6 months. An NSAID dose (with or without
other treatment) was stable for at least one month before
screening, and a prednisone (or equivalent corticosteroid)
dose ≤10mg/d was stable for at least one month before
screening.
Patients were ineligible for the study if they had been
treated with investigational drugs within one month of entry.
If a patient was taking a fish oil or borage oil supplement,
the dose was stable and ≤2000mg/d for each supplement for
2 months before screening. An intra-articular corticosteroid
injection within 6 months of screening excluded that joint
from evaluation until 6 months after injection. An aspartate
transaminase (AST) or alanine transaminase (ALT), or crea-
tinine > 1.5 times upper limit of normal, or a total bilirubin >
1.8mg/dL excluded patients.
4. Treatment
Patients were randomized to receive either 6 borage seed
oil (1.8 gm GLA) capsules plus 7 sunflower seed oil capsules
daily, or 7 fish oil (2.1 gm EPA/1.4 gm DHA) capsules and 6
sunflower seed oil capsules daily, or 6 borage seed oil capsules
plus 7 fish oil capsules daily. All capsules were identical in
appearance and color and were purchased from Bioriginal
Food and Service Corp., Saskatoon, Canada, who shipped the
capsules in coded opaque plastic bottles to the University of
Massachusetts University Hospital Pharmacy, from whence
they were distributed to participating centers. Capsules were
taken in 2 or 3 divided doses with meals.
5. Clinical Assessment
Each individual patient was evaluated by the same examiner
at each visit.The 4-valuemodified disease activity score using
ESR (DAS 28) was the primary outcome measure.
The DAS 28 has been validated [20] and is as represen-
tative of change in disease status as the ACR criteria [21]. A
validated [22] Clinical Disease Activity Index (CDAI), omit-
ting acute phase reactants, was also used. The CDAI is valid
for assessment of RA activity and treatment response [23].
Patients were evaluated at baseline and 3-month intervals.
Patients were instructed to maintain their typical diet.
Dietary 24 hr recalls were collected at baseline and 18months,
or the terminal visit.
6. Evaluation of Radiographs
Radiographs of hands and feet were obtained at baseline and
18 months, or early exit, unless the patient exited before 12
months. All available radiographs were scored for erosions
(scale 0–5) and joint space narrowing (0–4) by Dr. John T
Sharp. Erosion and narrowing scores were summed to estab-
lish a total score. Radiographs were evaluated in patient sets
without knowledge of the order taken or treatment received
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Reason dropped 
GI upsets 20 26.32
Capsules too large/too many 16 21.05
Lack of efficacy 7 9.21
Other 33 43.42
Total 76 100
Recruited: 156
Randomized: 150
Borage 
group: 52 
Combination 
group: 45
Fish group:
53 
Dropped: 
28 Dropped: 25Dropped: 23
Borage group: 
24
Combination 
group:  22
Fish group:
28
65 subjects out of 76 dropped before 9 months. 11 subjects out of 76 dropped
between 9 and 18 months.
Frequency (%)
Figure 1: Flow chart: patient recruitment and progress.
by the patient. Films were scored as described [24]. A total of
17 joints in each hand and wrist and 6 joints in each forefoot
were scored for erosions and narrowing. Maximum possible
scores were 230 for erosions and 184 for narrowing. Patients
were categorized as to whether they exhibited radiographic
evidence of progressive or nonprogressive disease [25].
7. Data Management and Statistical Analysis
A sample of 45 patients per group was needed for 80% power
for a difference of 0.6 in change inDASbetween groups.There
were 156 patients screened as eligible and 150 patients were
randomized. At 9 months there were approximately 31 per
group and at 18 months 26 per group.The number of patients
completing 18 months is shown in Figure 1. First screening
visit was in 11/2004 and last follow-up visit was in 5/2008.
7.1. Statistical Methods. Baseline characteristics were com-
pared among groups using analysis of variance (ANOVA) for
continuous covariates and Chi-square tests for dichotomous
covariates. For skewed continuous distributions a Kruskal-
Wallis test was used and for small cell sizes Fisher’s exact test.
Changes in DAS and CDAI were tested over time using linear
random effects models with patient random intercepts and
slope. DAS andCDAIweremodeled as a function of random-
ized group and time, and an interaction term of group and
time was used to test if trends were different by group. For
DAS, time was used as a categorical variable (3 time points).
For CDAI (7 time points), timewas continuous and estimated
lowess curves [26] indicated a quadratic association. Mean
changes from baseline in DAS and CDAI were based on the
models.
Sensitivity analyses were done, using completers (to 18
months) and two imputations: (1) dropped patients return
to baseline values and (2) multiple imputation for missing
outcomes [27–29]. Results between groups from all analyses
were similar. Statistical comparisons of trends among groups
were consistent in all models.
Use of TNF antagonists, NSAIDS, and corticosteroidswas
analyzed using logistic regression.
Change in X-ray scores between baseline and follow-up
was compared among groups using a Kruskal-Wallis test.
Changes in scores were compared to changes in DAS and
CDAI using Spearman correlations. Analyses examined the
absolute change and rate of change, and results from each
analysis were similar. Rate of change estimates are presented.
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Patients in this study were matched to patients in the
Consortium of Rheumatology Researchers of North America
(CORRONA), a large RA registry [30], selected to meet
the criteria for this study. We matched patients on the
components of the CDAI so disease activity was similar at
baseline. Trends in CDAI over time were compared between
the matched groups (patients in this study and CORRONA
patients) using random effects models.
8. Results
Among eligible patients, 150 were randomized. Patients
randomized to each group and the numbers completing the
18-month study are listed in Figure 1 including reasons for
dropouts. Given that beneficial effects of the oils can occur
2-3 months after onset of therapy, outcomes were evaluated
for patients in the trial for at least 12 weeks (138/150 = 92%).
The overall dropout rate (<18 months in the study) was 51%
and was not significantly different among the groups (borage:
54%; fish: 47%; combination 51%, 𝑃 = 0.79). The largest
proportion dropped due to size and number of capsules or
because of gastrointestinal problems (47%).
Randomized groups were balanced across all characteris-
tics (𝑃 ≥ 0.2 for all characteristics) (Table 1).
Baseline characteristics between completers (18 months)
and those who dropped were compared. The completers
were more likely to be male (24% versus 13%) and
African-American (11% versus 1%) and have lower patient
global scores (4.31 versus 5.38) and physician global scores
(4.24 versus 4.98) but higher swollen joint counts (14.12 versus
12.17) at the beginning of the study. CDAI and DAS were not
different (𝑃 > 0.76).
Compliance, assessed by capsule counts and patient
report, indicates that 45% of patients reported ever missing
a dose (borage: 42%, fish 48%, and combination 47%, 𝑃 =
0.77). Median total capsules missed (excluding those with 0)
were 182 (borage: 164, fish 169, and combination 256, 𝑃 =
0.65). Comparison of change in CDAI and DAS adjusted
for number of capsules missed did not change the group
comparisons.
9. Safety
No significant changes in dietary intake of fatty acids or
weight change were observed. Total reported adverse events
(AE) were comparable with rates of 1.65/person-year in
fish, 1.48/person-year in borage, and 1.73/person-year in
combined. With fish as the reference group the incident rate
ratios (IRR) were borage IRR = 0.9[0.66, 1.23] and combined
IRR = 1.05[0.77, 1.43].
If AEs are restricted to events that are “possibly related
to treatment,” then event rates are 0.30/person year for
fish, 0.46/person year for borage, and 0.77/person year for
combined. With fish as the reference group, borage IRR =
1.56[0.82, 2.95] and combined IRR = 2.61[1.44, 4.74]. All
related AEs were associated with gastrointestinal distress (all
but two were mild to moderate). Two patients dropped due
0
20
40
60
80
0 5 10 15 20
Oils Lowess oils
CORRONA Lowess CORRONA
CDAI over time in matched patients
Follow-up in months
Figure 2: Comparison of OILS Study and matched CORRONA pa-
tients. Lowess curve fits of CDAI over time (months) in the study
patients (OILS) and a matched set of patients from a rheumatoid
arthritis registry (CORRONA).
to Grade IV AEs: “burning in the throat” and severe nausea.
Both were in the borage group.
10. Clinical Responses
No significant differences were observed between groups in
trends in DAS over time (𝑃 = 0.45) (Table 2(a)). Estimated
changes in DAS in each group are shown in Table 2(a). When
all 3 groups were combined, a significant (𝑃 < 0.001)
reduction of 1.51 in DAS by 18mo was observed with nearly
all the decrease occurring by 9mo.
The same trends were noted in CDAI. There was no
significant difference in trend in CDAI over time among
the three groups (𝑃 = 0.15). Estimated changes in CDAI
are shown in Table 2(b). The combined groups exhibited a
significant reduction in CDAI (𝑃 < 0.001) over time and an
estimated reduction in CDAI of 12.5 by 9 months.
The distribution of therapy for RA is shown in Table 3.
There were no significant differences in therapy by group at
9 months and 18 months. There was no significant difference
between groups in change in medications over time.
Based on X-rays at baseline and follow-up (Table 4) there
were no significant differences between the 3 groups in the
combined scores (𝑃 = 0.38), erosion scores (𝑃 = 0.28),
or joint space narrowing scores (𝑃 = 0.27). There was a
significant increase in all scores over time. Radiographs from
8 patients (11%) exhibited a reduction in the combined Sharp
score, whereas 33 (45%) exhibited an increase, and 32 (44%)
showed no change.
Significant associations were not observed between
change in X-ray scores and change in DAS (Spearman 𝑟 =
0.20,𝑃 = 0.13) or CDAI (𝑟 = 0.06,𝑃 = 0.63), or with baseline
levels of DAS (𝑟 = −0.01, 𝑃 = 0.98) or CDAI (𝑟 = −0.02,
𝑃 = 0.86).
Trends in CDAI over time in patients in this study were
compared to matched patients from the CORRONA registry
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Table 1: Baseline characteristics in the three randomized groups.
Mean (SD) or median [IQR] (𝑛 = total)
or percent (𝑐 = num) (𝑛 = total)
Borage group
(𝑛 = 52)
Combination
group (𝑛 = 45)
Fish group
(𝑛 = 53) 𝑃 value
Body mass index (kg/m2) 29.4 (7.1)(𝑛 = 49)
30.4 (8.2)
(𝑛 = 45)
31.4 (9.5)
(𝑛 = 51) 0.499
Female 76.9 (𝑐 = 40) 80.0 (𝑐 = 36) 86.8 (𝑐 = 46) 0.415
Age 60.3 (9.2) 60.5 (13.0) 57.3 (12.3) 0.295
Black/African-American 7.8 (𝑐 = 4)(𝑛 = 51)
2.2 (𝑐 = 1)
(𝑛 = 45)
7.8 (𝑐 = 4)
(𝑛 = 51) 0.428
∗∗
Does subject exercise? (yes) 57.7 (𝑐 = 30) 51.1 (𝑐 = 23) 50.9 (𝑐 = 27) 0.738
Rheumatoid factor positive 73.9 (𝑐 = 34)(𝑛 = 46)
83.9 (𝑐 = 26)
(𝑛 = 31)
72.7 (𝑐 = 32)
(𝑛 = 44) 0.491
Log ESR value 2.9 (1.1)(𝑛 = 52)
2.7 (1.0)
(𝑛 = 43)
3.05 (1.0)
(𝑛 = 51) 0.199
CRP value 0.6 [0.3–1.5](𝑛 = 48)
0.6 [0.4–2.7]
(𝑛 = 40)
0.8 [0.4–1.7]
(𝑛 = 46) 0.415
∗
Disability index (mHAQ) 0.5 [0.1–0.7](𝑛 = 51)
0.5 [0.1–0.9]
(𝑛 = 45)
0.5 [0.1–0.9]
(𝑛 = 53) 0.788
∗
Clinical Disease Activity Index 34.4 (11.5) 36.0 (12.6) 35.8 (11.3) 0.763
Simplified Disease Activity Index 33.1 (27.0–47.1)(𝑛 = 48)
34.1 (28.8–50.2)
(𝑛 = 40)
35.5 (30.8–46.2)
(𝑛 = 46) 0.442
Disease activity score 5.0 [4.1–5.8](𝑛 = 52)
4.8 [3.9–5.7]
(𝑛 = 43)
5.2 [4.4–6.0]
(𝑛 = 51) 0.404
∗
DAS remission (<2.6) 3.8 (𝑐 = 2)(𝑛 = 52)
4.6 (𝑐 = 2)
(𝑛 = 43)
2.0 (𝑐 = 1)
(𝑛 = 51) 0.859
∗∗
Total number of tender joints 12.5
[7.5–18.0]
11.0
[7.0–18.0]
12.0
[8.0–20.0] 0.936
∗
Total number of swollen joints 12.0
[8.0–15.0]
12.0
[8.0–19.0]
12.0
[8.0–18.0] 0.733
∗
Physician global 3.8
[3.0–5.8]
4.0
[3.0–6.3]
4.1
[3.0–7.0] 0.646
∗
Patient global 5.0
[3.0–6.7]
5.5
[4.0–7.0]
5.0
[2.8–6.5] 0.435
∗
Patients taking methotrexate 61.5(𝑐 = 32)
68.9
(𝑐 = 31)
64.1
(𝑐 = 34) 0.748
Patients taking NSAIDS 28.8 (𝑐 = 15) 31.1 (𝑐 = 14) 26.4 (𝑐 = 14) 0.876
Patients taking corticosteroid 21.1(𝑐 = 11)
24.4
(𝑐 = 11)
28.3
(𝑐 = 15) 0.696
Patients taking DMARDS 71.1(𝑐 = 37)
77.8
(𝑐 = 35)
69.8
(𝑐 = 37) 0.647
Patients taking TNF blockers 50.0(𝑐 = 26)
44.4
(𝑐 = 20)
50.9
(𝑐 = 27) 0.791
Morning stiffness (minutes)
60.0
[30.0–180.0]
(𝑛 = 51)
60.0
[35.0–120.0]
(𝑛 = 45)
60.0
[42.5–120.0]
(𝑛 = 52)
0.439∗
Duration of rheumatoid arthritis (years) 7.4 [3.0–15.3](𝑛 = 52)
12.2 [4.4–18.0]
(𝑛 = 44)
6.3 [4.2–18.9]
(𝑛 = 51) 0.349
∗
∗
𝑃 value is from a Kruskal-Wallis test, median with the 25th and the 75th percentile is shown.
∗∗
𝑃 value is from a Fisher’s exact test. All other 𝑃 values come from a 𝑡-test or chi-square.
(Figure 2). No significant difference was seen in trends over
time between the two groups (𝑃 = 0.31).
Medication use was also compared.There were no signif-
icant differences in change in prednisone use (𝑃 = 0.81) or in
change in TNF antagonists (𝑃 = 0.99).There was a significant
difference in change in oralDMARDuse (𝑃 = 0.026) between
the two groups: patients in this study exhibited a decrease
in DMARD treatment (OR = 0.86 for one year, 𝑃 = 0.11),
whereas CORRONA patients had an increase in DMARD
treatment (OR = 1.20 for one year, 𝑃 = 0.11). This difference
manifests itself in the change in combination therapy (TNF
antagonist + oral DMARD). Patients treated with the oils
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Table 2: Change in DAS from baseline. Change in CDAI from baseline.
(a)
9 months 18 months
Borage group −1.33 (−1.83 to −0.84) −1.53 (−2.05 to −1.01)
Combination group −1.18 (−1.83 to −0.54) −1.28 (−1.88 to −0.67)
Fish group −1.56 (−2.16 to −0.96) −1.45 (−2.01 to −0.89)
(b)
Time point Borage group Combination group Fish group
Coef. 95% Conf. interval Coef. 95% Conf. interval Coef. 95% Conf. interval
3 months −6.75 −8.94 −4.57 −6.59 −8.98 −4.21 −10.69 −12.84 −8.54
6 months −9.26 −12.00 −6.52 −8.81 −11.81 −5.81 −14.37 −17.07 −11.67
9 months −11.20 −14.21 −8.19 −10.31 −13.61 −7.01 −16.95 −19.91 −13.98
12 months −12.55 −15.66 −9.45 −11.10 −14.50 −7.69 −18.42 −21.46 −15.37
15 months −13.34 −16.59 −10.09 −11.16 −14.70 −7.62 −18.78 −21.92 −15.63
18 months −13.54 −17.31 −9.77 −10.51 −14.57 −6.45 −18.03 −21.60 −14.45
Table 3: Distribution of medications at baseline, 9, and 18 months.
Baseline 9months
𝑃 value 18months 𝑃 value
𝑁 % 𝑁 % 𝑁 %
Using TNF antagonists 0.37 0.36
Borage group 26 50.0 18 58.1 12 48.0%
Combination group 20 44.4 11 40.7 10 45.4%
Fish group 27 50.9 16 44.4 19 63.3%
Using DMARDS 0.46 0.14
Borage group 37 71.1 23 74.2 16 64.0%
Combination group 35 77.8 21 77.8 19 86.4
Fish group 37 69.8 26 72.2 19 63.3
Using corticosteroids 0.47 0.07
Borage group 11 21.1 6 19.3 2 8.0
Combination group 11 24.4 9 33.3 8 36.4
Fish group 15 28.3 8 22.2 7 23.3
Using NSAIDS 0.49 0.19
Borage group 15 28.8 6 19.3 4 16.0
Combination group 14 31.1 9 33.3 8 36.4
Fish group 14 26.4 10 27.8 11 36.7
A comparison of change over time among groups for TNF blockers, DMARD, corticosteroid, and NSAID use showed no significant differences between the
groups. TNF blocker 𝑃 = 0.09, DMARDS 𝑃 = 0.38, corticosteroids 𝑃 = 0.32, and NSAIDS 𝑃 = 0.94.
reduced their combination therapy (OR = 0.85, 𝑃 = 0.03),
but CORRONA patients on TNF antagonists did not reduce
DMARD treatment (OR = 1.00, 𝑃 = 0.97).
11. Discussion
The premise that the combination of borage and fish oils
would be superior to either oil alone is not confirmed by this
study. All 3 treatment groups exhibited significant reductions
in bothDAS (1.5) andCDAI (12.5) at 9months, improvements
which persisted at 18 months. Given the efficacy of both
oils as treatment for RA [31] a placebo group was not
included. However, comparison with the clinical course in a
matched set of patients in the CORRONA Registry receiving
similar traditional treatment showed similar disease activity
trends. Evidence of a significant reduction in combination
therapy (oral DMARD + TNF antagonist) by study patients
versus patients from the RA registry suggests that treatment
with the oils allowed reduction of treatment with more
toxic agents. In randomized, placebo-controlled clinical trials
in patients with RA, EPA/DHA and GLA rich oils may
replace NSAIDs and do not cause adverse events associated
with NSAID administration [32]. Our observations [33] that
DGLA suppresses synovial cell proliferation and results of
a controlled trial [32] which indicate that RA patients are
more improved after 12 months of GLA treatment than after
6 months suggest that GLA might function as a DMARD.
No differences in X-ray progression were observed
among the 3 groups. Changes in radiographic scores did
not correlate with clinical responses (DAS and CDAI). These
Evidence-Based Complementary and Alternative Medicine 7
Table 4: Radiograph Scores.
Mean (SD)
Median [interquartile range] Baseline Follow-up
Score
change/year 𝑃 value
Combined score
Borage 𝑛 = 25 17.8 (29.4)7.0 [1.0, 19.0]
18.8 (28.8)
7.0 [3.0, 27.0] 0.69 (2.3) 𝑃 = 0.38
∗
Combination 𝑛 = 18 49.2 (54.6)27 [10.0, 94.0]
50.8 (56.8)
26.5 [10.0, 95.0] 1.07 (3.0)
Fish 𝑛 = 30 23.1 (33.1)7.0 [0.0, 33.0]
26.5 (35.5)
8.0 [0.0, 41.0] 2.27 (6.3)
All groups 27.7 (39.9)9.0 [1.0, 39.0]
29.8 (41.3)
11.0 [3.0, 41.0] 1.44 (4.5) 𝑃 < 0.001
+
Erosions score
Borage 6.5 (11.4)2.0 [0.0, 8.0]
7.1 (11.3)
4.0 [1.0, 8.0] 0.44 (1.3) 𝑃 = 0.28
∗
Combination 22.9 (25.4)10.0 [2.0, 46.0]
23.1 (25.9)
10.0 [2.0, 46.0] 0.12 (0.8)
Fish 10.4 (14.8)3.0 [0.0, 17.0]
11.6 (17.4)
3.0 [0.0, 16.0] 0.85 (3.6)
All groups 12.1 (18.0)3.0 [0.0, 15.0]
12.9 (19.0)
4.0 [1.0, 14.0] 0.53 (2.5) 𝑃 = 0.003
+
Joint space narrowing score
Borage 11.3 (19.1)3.0 [0.0, 16.0]
11.7 (18.9)
3.0 [0.0, 18.0] 0.25 (1.6) 𝑃 = 0.27
∗
Combination 26.3 (31.0)16.0 [5.0, 41.0]
27.8 (32.3)
16.5 [5.0, 42.0] 0.96 (2.6)
Fish 12.7 (20.0)4.5 [0.0, 15.0]
14.8 (20.9)
5.0 [0.0, 25.0] 1.43 (3.7)
All groups 15.6 (23.4)5.0 [0.0, 19.0]
16.9 (24.1)
5.0 [0.0, 25.0] 0.91 (2.9) 𝑃 = 0.003
+
∗Test of change among groups.
+Test of change over time in groups combined.
findings are in agreement with known clinical observations
that some patients who experience substantial improvement
in joint pain and swelling exhibit worsening of joints as
assessed by radiography and to similar findings from con-
trolled clinical trials [34]. It is likely that agents that reduce
inflammatory responses, resulting in reduction of joint pain
and swelling, do not influence pathways leading to joint tissue
injury.
All treatments were safe. Rates and types of adverse
events were similar across all 3 treatment groups and were
related almost entirely to the large size and number of
capsules and to gastrointestinal distress. Although we have
not observed increases in circulating arachidonic acid (AA)
after administration of borage seed oil, the possibilitymust be
considered in long term treatment. When fish oil is admin-
istered with borage oil to healthy individuals, bioconversion
of GLA to AA is prevented [35]. Thus, consideration can
be given to the use of one or another or both of these oils
for treatment of RA. Although NSAIDs act rapidly, adverse
events associated with NSAID use are well known [36]. The
delay in symptomatic relief with marine and botanical oils
(8–12 weeks) should be acceptable for treatment of a chronic
condition such as RA. Neither borage oil nor fish oil is
associated with serious gastrointestinal events (ulceration,
bleeding, and perforation). In addition, whereas NSAIDs
increase the incidence of myocardial infarction and stroke
[37], fish oil reduces cardiovascular events in patients at risk,
including those with RA [38].
Unfortunately, as is the case for studies in which fish oil
was used to reduce cardiovascular events [38], the dropout
rate in our trial was in excess of 45%. Much of that problem
is due to the large size and number of capsules administered
each day. It would be preferable to use isolated fatty acids
which can be formulated in higher concentrations in small
capsules. Among those patients who did not complete the
18-month trial, a sufficient number remained for at least 12
weeks, to allow evaluation (Table 2).
Patients who completed the entire 18-month trial were
mainly male and African American, despite the fact that this
group had higher swollen joint counts at baseline. That may
reflect the problem of access to health care for people of color
in the United States [39]. Patients who struggle to purchase
health insurance and traditionalmedicinemay bemore likely
to stay the course in a study that provides treatment and care.
Although the combination of oils did not prove superior
to either oil alone, patients in each group did improve
significantly, so that most patients had incentive to continue
the trial. In addition, these oils can substitute forNSAIDs, and
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the combination of both oils allows reduction of more toxic
DMARDs by patients treated with agents that block TNFa.
Newer formulations which provide appropriate fatty acids in
smaller capsules would encourage more patients to use them
rather than NSAIDs. Further studies of the combination of
marine and botanical oils might provide data to persuade
physicians to use them in treatment of patients on DMARDs
and biologic agents, in an effort to reduce treatment with the
more toxic DMARDs.
Key Messages
Treatment of RA with oils reduced disease activity; disease
activity reduction is similar for fish oil, borage seed oil, and
the combination of both oils; treatment with oils reduced
administration of more toxic therapy.
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